![Diabetes Core Update artwork](https://is5-ssl.mzstatic.com/image/thumb/Podcasts113/v4/55/52/bc/5552bc45-1fd0-1bb9-3d3c-9675074debc3/mza_5338079106576623083.jpg/100x100bb.jpg)
Diabetes Core Update: Therapeutic Inertia – April 2020
Diabetes Core Update
English - April 14, 2020 19:00 - 22 minutes - 41.1 MB - ★★★★★ - 85 ratingsMedicine Health & Fitness primary care diabetes endocrine family internal medical medicine Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
In this first episode of a three-part series on “Disrupting Therapeutic Inertia in Diabetes Management,” Drs. John Russell and Neil Skolnik examine a case study of a 55-year-old man with type 2 diabetes (3 years duration, A1C 8.2%). In so doing, they review six articles that define achievement gaps in reaching A1C goals and the reasons for why those gaps exist. In episodes 2 and 3 of this series, Drs. Russell and Skolnik we will look at additional causes of therapeutic inertia and solutions for overcoming it. This special three-part series on therapeutic inertia is supported by independent educational grant from Sanofi (https://www.sanofi.com).
This issue will review:
Achievement of target therapeutic goals in persons with T2DM Achievement of therapeutic goals from 2005 – 2015 Clinical Inertia in Newly Diagnosed Type 2 DM Clinical Inertia over Time in Type 2 DM Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use Difference between Clinical Trial and Real-World Studies Achievement of Target A1C <7.0% in Patients Treated with Basal Insulin in RCTs and Clinical PracticeFor more information about each of ADA’s science and medical journals, please visit www.diabetesjournals.org.
Presented by:
Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health
In this first episode of a three-part series on “Disrupting Therapeutic Inertia in Diabetes Management,” Drs. John Russell and Neil Skolnik examine a case study of a 55-year-old man with type 2 diabetes (3 years duration, A1C 8.2%). In so doing, they review six articles that define achievement gaps in reaching A1C goals and the reasons for why those gaps exist. In episodes 2 and 3 of this series, Drs. Russell and Skolnik we will look at additional causes of therapeutic inertia and solutions for overcoming it. This special three-part series on therapeutic inertia is supported by independent educational grant from Sanofi (https://www.sanofi.com).
This issue will review:
Achievement of target therapeutic goals in persons with T2DM Achievement of therapeutic goals from 2005 – 2015 Clinical Inertia in Newly Diagnosed Type 2 DM Clinical Inertia over Time in Type 2 DM Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use Difference between Clinical Trial and Real-World Studies Achievement of Target A1C